Aggregation of tau protein is a pathological hallmark of Alzheimer's disease and other neurodegenerative tauopathies. Inhibition of tau aggregation may provide a method for treatment of these disorders. Methods to identify tau aggregation inhibitors (TAIs) in vitro are useful and here we describe assays for TAIs using purified recombinant tau protein fragments in a cell-free immunoassay format and in a stably transfected cell model to create a more physiological environment.
Keywords: Alzheimer’s disease; ELISA; Immunoassay; Tau aggregation inhibitor; Tau protein.
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.